# Pfizer begins late-stage trial for new pneumococcal shot in infants after strong Phase 2 data.

*biotech · news · 2026-05-20 · Seeking Alpha*

## Key points

- Pfizer has initiated a Phase 3 trial for its 25-valent pneumococcal vaccine in infants.
- The new 25vPnC vaccine outperformed Prevnar 20 in Phase 2 trials for infants.
- 25vPnC targets more pneumococcal strains than the currently approved Prevnar 20 vaccine.
- This Phase 3 study marks a significant step toward potentially replacing or supplementing Prevnar 20.

**Companies:** Pfizer
**Countries:** United States

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4595237-pfizer-begins-late-stage-trial-pneumococcal-shot-infants)

---

Canonical: https://newsio.io/n/41334fde-3c12-4eaf-a2b9-378c495dce73/pfizer-begins-late-stage-trial-for-new-pneumococcal-shot-in-infants-after-strong
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works